Publication | Open Access

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Kinase InhibitorMedicinePharmacologyCheckpoint 1Immune Checkpoint InhibitorPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer ResearchPemetrexed 500